J. C. Slish, L. M. Catanzaro, Q. Ma, O. O. Okusanya, L. Demeter, M. Albrecht and G. D. Morse Pages 1129 - 1145 ( 17 )
The observed inter-individual variation in antiretroviral pharmacokinetics (PK) that results in a wide range of drug exposures from fixed-dose regimens has led to increasing interest in the clinical use of therapeutic drug monitoring (TDM) to individualize dosing of antiretroviral therapy (ART). The focus of this review is to provide an overview of literature available to support therapeutic drug monitoring among the current classes of antiretrovirals, suggest patient populations that may benefit from TDM and bring forth some of the limitations that may exist for widespread use of TDM in a traditional clinical setting.
HIV enteropathy,P-glycoprotein,CXCR4 inhibitors,CYP450 system,HIV-1 protease inhibitors (PIs),adherence
, , , , , , University at Buffalo Schoolof Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice,315 Cooke Hall, Buffalo, NY 14260, USA.